The magic bullet: Niclosamide

Area of Science:

• Oncology
• Drug Discovery
• Cancer Biology

Background:

• The concept of a 'magic bullet' drug for cancer remains elusive with current therapies.
• Existing cancer treatments like chemotherapy and radiation have limitations in specificity and efficacy.
• Niclosamide, an FDA-approved anthelmintic, exhibits promising broad-spectrum anti-cancer properties.

Purpose of the Study:

• To review the functions and mechanisms of niclosamide as a potential cancer 'magic bullet'.
• To summarize niclosamide's multi-targeted inhibition of oncogenic pathways and activation of tumor suppressors.
• To discuss niclosamide's potential role in improving cancer immunotherapy and its clinical applications.

Main Methods:

• Review of pre-clinical studies on niclosamide's anti-cancer activity.
• Analysis of niclosamide's effects on multiple oncogenic and tumor suppressor signaling pathways.
• Investigation of niclosamide's impact on cellular metabolism and epigenetic remodeling.

Main Results:

• Niclosamide inhibits key cancer pathways including Wnt/β-catenin, Ras, Stat3, Notch, E2F-Myc, NF-κB, and mTOR.
• Niclosamide activates tumor suppressor pathways such as p53, PP2A, and AMPK.
• Niclosamide ethanolamine (NEN) reprograms cellular metabolism, remodels epigenetics, and promotes differentiation.

Conclusions:

• Niclosamide demonstrates significant potential as a 'magic bullet' cancer therapy due to its broad efficacy and safety profile.
• Niclosamide's ability to target multiple pathways and modulate the tumor microenvironment offers a novel therapeutic strategy.
• Ongoing clinical trials are evaluating niclosamide's therapeutic effects in cancer patients, highlighting its promising future in oncology.